Mitoxantrone does not restore the impaired suppressive function of natural regulatory t cells in patients suffering from multiple sclerosis

European Neurology

Volumn 61, Issue 1, 2008, Pages 27-32

  Putzki, Norman ^a,b   Kumar, Manoj ^a   Kreuzfelder, Ernst ^a   Grosse Wilde, Hans ^a   Diener, H C ^a   Limmroth, Volker ^a,c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Humoral immunity; Mitoxantrone; T regulatory cells

Indexed keywords

MITOGENIC AGENT; MITOXANTRONE; MYELIN BASIC PROTEIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; B LYMPHOCYTE; CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; FEMALE; HUMAN; HUMORAL IMMUNITY; IN VITRO STUDY; LONGITUDINAL STUDY; LYMPHOCYTE FUNCTION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STIMULATION; CELL PROLIFERATION; CLINICAL TRIAL; FLOW CYTOMETRY; IMMUNOLOGY;

B-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MITOXANTRONE; MULTIPLE SCLEROSIS; T-LYMPHOCYTES, REGULATORY;

EID: 54249126917     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000165346     Document Type: Article

References (22)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
2. Raine CS, Cross AH: Axonal dystrophy as a consequence of long-term demyelination. Lab Invest 1989; 60: 714-725. (Pubitemid 19154520)
3. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285. (Pubitemid 28065253)
4. Lassmann H, Brück W, Lucchinetti C: Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-121. (Pubitemid 32201673)
5. Rieckmann P, Toyka KV: Escalating immunotherapy of multiple sclerosis: Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group (MSTCG). Eur Neurol 1999; 42: 121-127.
6. Yong VW: Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802-808.
7. Hartung HP, Gonsette R, Konig N, et al: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-2025. (Pubitemid 36026580)
8. Chan A, Weilbach FX, Toyka KV, Gold R: Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2004; 139: 152-158.
9. Gbadamosi J, Buhmann C, Tessmer W, Moench A, Haag F, Heesen C: Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol 2003; 49: 137-141. (Pubitemid 36359460)
10. Noseworthy JH: Progress in determining the causes and treatment of multiple sclerosis. Nature 1999; 399:A40-A47.
11. Steinman L: Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996; 85: 299-302. (Pubitemid 26160700)
12. Maloy KJ, Powrie F: Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2: 816-822.
13. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA: Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971-979. (Pubitemid 38481088)
14. Kumar M, Putzki N, Limmroth V, Remus R: CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic induced proliferation in patients with multiple sclerosis. J Neuroimmunol 2006; 180: 178-184. (Pubitemid 44767710)
15. Haas J, Hug A, Viehoever A, Fritzsching B, et al: Reduced suppressive effect of CD4+CD25+ regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoproteins in patients with multiple sclerosis. Eur J Immunol 2005; 35: 562-567.
16. Poser CM, Paty DW, Scheinberg L, et al: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231. (Pubitemid 13158528)
17. Ditschkowski M, Kreuzfelder E, Rebmann V, et al: HLA-DR expression and soluble HLADR levels in septic patients after trauma. Ann Surg 1999; 229: 246-254. (Pubitemid 30191799)
18. Hafler DA, Slavik JM, Anderson DE, et al: Multiple sclerosis. Immunol Rev 2004; 204: 208-231.
19. Gonsette RE: Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler 1996; 1: 329-332. (Pubitemid 126701292)
20. Mauch E, Kornhuber HH, Krapf H, et al: Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatr Clin Neurosci 1992; 242: 96-102. (Pubitemid 23023578)
21. Gonsette RE, Demonty L: Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 1990; 40(suppl):261-266.
22. De Andres C, Aristimuno C, de las Heras V, et al: Interferon beta-1a therapy enhances CD4+ regulatory T cell function: an ex vivo and in vitro longitudinal study in relapsingremitting multiple sclerosis. J Neuroimmunol 2007; 182: 204-211. (Pubitemid 46026708)